Maxion names new CBO, Sotio promotes pair

Joel Edwards joined Cambridge, U.K.-based Maxion Therapeutics Ltd. as CBO, a role he previously held at Abilita Therapeutics Inc. and Biosion Inc. Maxion is developing antibody-based “KnotBody” therapies for diseases driven by ion channels and GPCRs. 

Sotio a.s. promoted Amy Jensen-Smith to CSO and Ulrich Moebius to chief development officer. Jensen-Smith was VP of Sotio U.S. and head of discovery; before joining the Czech company in 2020, she worked on CAR and TCR T cell programs at bluebird bio Inc. Moebius has served as head of preclinical development since joining the company in 2017. He was previously CSO of Pieris AG. Sotio, part of the PPF Group, is developing antibody-drug conjugates and immunotherapies for hard-to-treat solid tumors...